Yehezkel Ben-Ari: The Neuroarcheology concept: From brain development to predicting, understanding, and treating brain disorders

Spanning over four decades at France's premier research institutions (CNRS and INSERM), Dr. Yehezkel Ben-Ari's groundbreaking neuroscience research has fundamentally transformed our understanding of brain development through his seminal discovery of the GABA excitatory-to-inhibitory developmental shift, an evolutionary conserved principle later validated across all species from worms to humans. After directing the INSERM unit at Port-Royal Maternity and founding the Mediterranean Institute of Neurobiology (INMED), Ben-Ari's unexpected observation of GABA's paradoxical excitatory role in immature neurons, which he initially set aside for over a year before recognizing its significance earned him prestigious recognitions including the Grand Prix INSERM, the Milken award of the Epilepsy Foundation of America (EFA) and an award from the European Society of Epilepsy. In this Genomic Press Interview, Ben-Ari reflects on his scientific journey, including his transition after French mandatory retirement to founding innovative therapeutic ventures targeting autism spectrum disorders, epilepsy, and brain tumors based on his unifying “Neuroarcheology” concept, proposing that many neurological disorders stem from developmental mechanisms that can be targeted with specific medications like bumetanide, which has shown promising results in clinical trials by modulating chloride transporters. While continuing to teach at the Pasteur Institute's brain development doctoral program, Ben-Ari's career exemplifies how persistence in investigating unexpected observations can lead to transformative discoveries with profound clinical implications, bridging the gap between fundamental neuroscience research and innovative therapeutic applications for previously untreatable neurological conditions.